DrugPatentWatch Database Preview
DEPO-SUBQ PROVERA 104 Drug Profile
» See Plans and Pricing
Which patents cover Depo-subq Provera 104, and what generic alternatives are available?
Depo-subq Provera 104 is a drug marketed by Pharmacia And Upjohn and is included in one NDA. There is one patent protecting this drug.
This drug has forty-three patent family members in twenty-nine countries.
The generic ingredient in DEPO-SUBQ PROVERA 104 is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.
US ANDA Litigation and Generic Entry Outlook for Depo-subq Provera 104
A generic version of DEPO-SUBQ PROVERA 104 was approved as medroxyprogesterone acetate by BARR on August 9th, 1996.
Summary for DEPO-SUBQ PROVERA 104
International Patents: | 43 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 71 |
Clinical Trials: | 52 |
Patent Applications: | 3,934 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DEPO-SUBQ PROVERA 104 at DailyMed |

Recent Clinical Trials for DEPO-SUBQ PROVERA 104
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 |
MU-JHU CARE | Phase 4 |
University of California, San Diego | Early Phase 1 |
Pharmacology for DEPO-SUBQ PROVERA 104
Drug Class | Progestin |
US Patents and Regulatory Information for DEPO-SUBQ PROVERA 104
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacia And Upjohn | DEPO-SUBQ PROVERA 104 | medroxyprogesterone acetate | INJECTABLE;SUBCUTANEOUS | 021583-001 | Dec 17, 2004 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DEPO-SUBQ PROVERA 104
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pharmacia And Upjohn | DEPO-SUBQ PROVERA 104 | medroxyprogesterone acetate | INJECTABLE;SUBCUTANEOUS | 021583-001 | Dec 17, 2004 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DEPO-SUBQ PROVERA 104
Country | Patent Number | Estimated Expiration |
---|---|---|
New Zealand | 522324 | Start Trial |
World Intellectual Property Organization (WIPO) | 0187266 | Start Trial |
Denmark | 1282402 | Start Trial |
Czech Republic | 303872 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for DEPO-SUBQ PROVERA 104
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0113964 | 97C0037 | Belgium | Start Trial | PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |